The evolution of aldosterone antagonists

被引:122
作者
Garthwaite, SM [1 ]
McMahon, EG [1 ]
机构
[1] Pfizer Inc, Global Project Managament, Skokie, IL USA
关键词
aldosterone; spironolactone; eplerenone; aldosterone blockers; aldosterone antagonists; selectivity;
D O I
10.1016/j.mce.2003.10.005
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Since the isolation and purification of aldosterone from adrenal extracts 50 years ago (Experientia 9 (1953) 33), scientists have learned a great deal about how and where aldosterone acts, the factors that control its release, what is its role in the pathophysiology of cardiovascular disease. how to make and study aldosterone antagonists, and for what medical purposes these agents are useful. In this paper, we will discuss the evolution of aldosterone antagonists from the relatively nonselective spironolactone (Aldactone(R)), to the highly selective eplerenone (Inspra(R)). Eplerenone represents a molecule with improved steroid receptor selectivity and pharmacokinetic properties ill man compared to spironolactone. Recent clinical results have demonstrated that these improvements translate into tolerability and efficacy in patients with cardiovascular disease. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:27 / 31
页数:5
相关论文
共 50 条
  • [1] Aldosterone Antagonists in Heart Failure
    Miller, Susan E.
    Alvarez, Rene J., Jr.
    JOURNAL OF CARDIOVASCULAR NURSING, 2013, 28 (06) : E47 - E54
  • [2] Antihypertensive therapy: Role of aldosterone antagonists
    Grandi, AM
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (17) : 2235 - 2242
  • [3] Aldosterone antagonists revisited
    Swolinsky, Jutta
    Schmidt-Ott, Kai
    NEPHROLOGIE, 2022, 17 (04): : 239 - 245
  • [4] Aldosterone antagonists in the treatment of hypertension
    Siewaszewicz, Ewa
    ARTERIAL HYPERTENSION, 2010, 14 (03): : 216 - 226
  • [5] Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension
    Dudenbostel, Tanja
    Calhoun, David A.
    AMERICAN JOURNAL OF HYPERTENSION, 2017, 30 (02) : 103 - 109
  • [6] The risks and benefits of aldosterone antagonists.
    Sica D.A.
    Current Heart Failure Reports, 2005, 2 (2) : 65 - 71
  • [7] Aldosterone receptor antagonists
    Azizi, Michel
    ANNALES D ENDOCRINOLOGIE, 2021, 82 (3-4) : 179 - 181
  • [8] Aldosterone antagonists - first choice in resistant hypertension
    Holzgreve H.
    MMW - Fortschritte der Medizin, 2016, 158 (7) : 65 - 70
  • [9] Aldosterone antagonists in the treatment and prevention of heart failure
    Boxer R.S.
    Dunlap M.E.
    Current Treatment Options in Cardiovascular Medicine, 2005, 7 (6) : 431 - 436
  • [10] The use of selective aldosterone antagonists
    Myron H. Weinberger
    Current Hypertension Reports, 2004, 6 : 342 - 345